Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical ...

New results from the Phase III MATTERHORN trial show AstraZeneca’s Imfinzi combination reduced the risk of death by 22% versus chemotherapy alone, marking a major advance for patients with resectable ...

See how early patient inclusion, integrated regulatory planning, and seamless CRO partnerships can help biotechs accelerate ...

Patient-reported outcomes (PROs) are widely used in oncology clinical trials to capture patients’ own perspectives on ...

Praxis Precision Medicines has shared positive data from its Phase III Essential3 clinical trial program (NCT06087276) assessing ulixacaltamide in essential tremor (ET). Across two studies, the small ...

The best option is to deploy semi-autonomous models where agents recommend actions, but humans validate and approve those actions. As reliability grows over time, organizations will increase their ...

As pharma wrestles with whether to trust fully autonomous AI, semi-autonomous agents are emerging as a safer middle ground that reduces manual work, eliminates white space in clinical development, and ...

Effective retention strategies should be integrated into trial design from the start, focusing on participant-centric ...

Understand how intelligent study design, focused data collection, and faster analytics can help clinical teams deliver meaningful results that sustain investor momentum. Gain insight into why early ...

Understand how intelligent study design, focused data collection, and faster analytics can help clinical teams deliver meaningful results that sustain investor momentum.

Eli Lilly’s oral GLP-1 therapy, orforglipron, met all primary and key secondary endpoints in the Phase III ACHIEVE-2 and ACHIEVE-5 studies, showing significant A1C reduction, weight loss, and ...

Preserving trial integrity. Clinical trials are susceptible to timing. Delays in investigational product delivery can stall ...